.Pharmacolibrary.Drugs.D_Dermatologicals.D11A_OtherDermatologicalPreparations.D11AH08_Abrocitinib.Abrocitinib .Pharmacolibrary.Drugs.D_Dermatologicals.D11A_OtherDermatologicalPreparations.D11AH08_Abrocitinib.Abrocitinib| name: | Abrocitinib | |
| ATC code: | D11AH08 | |
| route: | oral | |
| compartments: | 2 | |
| dosage: | 200 | mg |
| volume of distribution: | 103 | L |
| clearance: | 36.9 | L/h |
| other parameters in model implementation | ||
Abrocitinib is an oral Janus kinase 1 (JAK1) inhibitor indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents. It is approved for clinical use in several regions, including the US and EU.
Reported from healthy adult subjects after oral administration of a single 200 mg dose in phase I studies.
Le, M, et al., & Litvinov, IV (2021). Systematic Review on the Efficacy and Safety of Oral Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis. Frontiers in medicine 8 682547–None. DOI:10.3389/fmed.2021.682547 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34540860